Rituximab biosimilars comparison
BiosimilarsCompare rituximab biosimilars to brand Rituxan. Rituximab is FDA-approved for NHL, CLL, RA and other conditions on its label. Biosimilars offer significant cost savings for this widely used infusion therapy.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Rituxan (reference) | Genentech/Roche | IV infusion | Varies by indication (2 doses for RA, 4–8 cycles for oncology) | Original reference product; decades of clinical experience |
| Truxima (rituximab-abbs) | Celltrion | IV infusion | Same as reference | First FDA-approved rituximab biosimilar |
| Ruxience (rituximab-pvvr) | Pfizer | IV infusion | Same as reference | Pfizer biosimilar; widely available |
| Riabni (rituximab-arrx) | Amgen | IV infusion | Same as reference | Amgen biosimilar; competitive pricing |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.